COX-2: A target for colon cancer prevention

被引：256
|
作者：
Marnett, LJ
DuBois, RN
机构：
[1] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Cell Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2002年 / 42卷
关键词：
cyclooxygenase; prostaglandins; NSAIDs; cancer; prevention;
D O I：
10.1146/annurev.pharmtox.42.082301.164620
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence: is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.
引用
收藏
页码：55 / +
页数：26
相关论文
共 50 条
  • [31] Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities
    Mohsin, Noor Ul Amin
    Aslam, Sana
    Ahmad, Matloob
    Irfan, Muhammad
    Al-Hussain, Sami A.
    Zaki, Magdi E. A.
    PHARMACEUTICALS, 2022, 15 (12)
  • [32] Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression
    Ishikawa, Tomo-o
    Herschman, Harvey R.
    CARCINOGENESIS, 2010, 31 (04) : 729 - 736
  • [33] Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells
    Maier, TJ
    Schilling, K
    Schmidt, R
    Geisslinger, G
    Grösch, S
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (08) : 1469 - 1478
  • [34] Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease
    Ruan, Cheng-Huai
    So, Shui-Ping
    Ruan, Ke-He
    LIFE SCIENCES, 2011, 88 (1-2) : 24 - 30
  • [35] COX-2 in cancer: Gordian knot or Achilles heel?
    Stasinopoulos, Ioannis
    Shah, Tariq
    Penet, Marie-France
    Krishnamachary, Balaji
    Bhujwalla, Zaver M.
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [36] COX-2 and atherosclerosis
    Cipollone, Francesco
    Fazia, Maria Luigia
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 : S26 - S36
  • [37] Correlation between COX-2 and APC Expression in Left Versus Right-sided Human Colon Cancer
    Nasir, A.
    Lopez, A.
    Boulware, D.
    Malafa, M.
    Coppola, D.
    ANTICANCER RESEARCH, 2011, 31 (06) : 2191 - 2195
  • [38] COX-2 and the kidney
    Harris, Raymond C.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 : S37 - S42
  • [39] Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
    Debabrata Mukherjee
    Eric J Topol
    Arthritis Res Ther, 5
  • [40] Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
    Fosslien, E
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2000, 37 (05) : 431 - 502
12345